Merck
  • Home
  • Search Results
  • Analysis of changes in SUMO-2/3 modification during breast cancer progression and metastasis.

Analysis of changes in SUMO-2/3 modification during breast cancer progression and metastasis.

Journal of proteome research (2014-07-30)
Divya Subramonian, Sarita Raghunayakula, Jesper V Olsen, Karen A Beningo, Wulf Paschen, Xiang-Dong Zhang
ABSTRACT

SUMOylation is an essential posttranslational modification and regulates many cellular processes. Dysregulation of SUMOylation plays a critical role in metastasis, yet how its perturbation affects this lethal process of cancer is not well understood. We found that SUMO-2/3 modification is greatly up-regulated in metastatic breast cancer cells compared with nonmetastatic control cells. To identify proteins differentially modified by SUMO-2/3 between metastatic and nonmetastatic cells, we established a method in which endogenous SUMO-2/3 conjugates are labeled by stable isotope labeling by amino acids in cell culture (SILAC), immunopurified by SUMO-2/3 monoclonal antibodies and epitope-peptide elution, and analyzed by quantitative mass spectrometry. We identified 66 putative SUMO-2/3-conjugated proteins, of which 15 proteins show a significant increase/decrease in SUMO-2/3 modification in metastatic cells. Targets with altered SUMOylation are involved in cell cycle, migration, inflammation, glycolysis, gene expression, and SUMO/ubiquitin pathways, suggesting that perturbations of SUMO-2/3 modification might contribute to metastasis by affecting these processes. Consistent with this, up-regulation of PML SUMO-2/3 modification corresponds to an increased number of PML nuclear bodies (PML-NBs) in metastatic cells, whereas up-regulation of global SUMO-2/3 modification promotes 3D cell migration. Our findings provide a foundation for further investigating the effects of SUMOylation on breast cancer progression and metastasis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
乙腈, anhydrous, 99.8%
Sigma-Aldrich
乙腈, HPLC Plus, ≥99.9%
Sigma-Aldrich
L -还原型谷胱甘肽, ≥98.0%
Sigma-Aldrich
碳酸氢铵, ReagentPlus®, ≥99.0%
Sigma-Aldrich
乙腈, for HPLC, for UV, ≥99.9% (GC)
Sigma-Aldrich
碳酸氢铵, BioUltra, ≥99.5% (T)
Sigma-Aldrich
乙腈, ACS reagent, ≥99.5%
Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
L -还原型谷胱甘肽, suitable for cell culture, BioReagent, ≥98.0%, powder
Sigma-Aldrich
乙腈 溶液, contains 0.1 % (v/v) trifluoroacetic acid, suitable for HPLC
Sigma-Aldrich
L -还原型谷胱甘肽, BioXtra, ≥98.0%
Supelco
谷胱甘肽, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
乙腈, suitable for HPLC-GC, ≥99.8% (GC)
谷胱甘肽, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
乙腈, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.5% (GC)
Supelco
乙腈, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
乙腈, analytical standard
Sigma-Aldrich
乙腈, biotech. grade, ≥99.93%
Sigma-Aldrich
辛二酸双(N-羟基琥珀酰亚胺酯), ≥95%, powder
Sigma-Aldrich
乙腈, electronic grade, 99.999% trace metals basis
Sigma-Aldrich
乙腈, ReagentPlus®, 99%
Supelco
残留溶剂-乙腈, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
乙腈, suitable for DNA synthesis, ≥99.9% (GC)
USP
乙腈 溶液, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
乙腈, ≥99.5% (GC)